We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
- Authors
Kahn, Steven E; Haffner, Steven M; Viberti, Giancarlo; Herman, William H; Lachin, John M; Kravitz, Barbara G; Yu, Dahong; Paul, Gitanjali; Holman, Rury R; Zinman, Bernard; Diabetes Outcome Progression Trial (ADOPT) Study Group
- Abstract
C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; however, the long-term effects of those agents are unknown.
- Publication
Diabetes care, 2010, Vol 33, Issue 1, p177
- ISSN
1935-5548
- Publication type
Journal Article
- DOI
10.2337/dc09-1661